Prolia (Denosumab): What People Actually Pay and Real Results From Women Who've Used It

What Does Prolia (Denosumab) Actually Cost?

The cash price for one Prolia injection sits between $1,200 and $1,400 in the United States for 2024. Because Prolia is given every six months, the annual out-of-pocket cost without any insurance or assistance program lands around $2,400 to $2,800 per year. That is high, and it matters when you are planning a treatment that may run for years.

Cost, however, varies significantly based on how you access the drug.

Medicare Part B Coverage

Prolia is administered in a clinician's office, which means it falls under Medicare Part B (medical benefits) rather than Part D (prescription drug benefits). Medicare Part B covers injectable osteoporosis drugs at 80% after your deductible, and most supplemental (Medigap) plans cover the remaining 20%. In practice, many women on Medicare with a Medigap plan pay between $0 and $80 per injection.

Commercial Insurance

Most large commercial plans cover Prolia for postmenopausal osteoporosis when you meet a T-score threshold (typically T-score <-2.5 or <-2.0 with a prior fracture). A prior authorization is almost always required. Copays after PA approval typically range from $0 to $150 per injection depending on your formulary tier.

Amgen's Assistance Programs

Amgen, Prolia's manufacturer, runs the Amgen Safety Net Foundation for uninsured patients who meet income criteria, providing free drug. For commercially insured women, the Prolia co-pay card has historically capped out-of-pocket costs at $0 per dose for eligible patients, though program terms change annually. Call 1-800-772-6436 to check current eligibility.

What Women on Reddit Say About Cost

On r/osteoporosis and r/Autoimmune, the most common thread about Prolia is not about side effects. It is about insurance fights. A representative comment from a 64-year-old poster in late 2024: "My insurance denied it twice saying I needed to 'fail' a bisphosphonate first. My rheumatologist had to write a detailed letter. Took six weeks but it was eventually approved." Several women in those threads describe using Good Rx for other drugs but note that Good Rx coupons do not apply to Prolia because it is a provider-administered injectable rather than a retail pharmacy fill.

The WomanRx Cost Navigation Framework for Prolia:

1. Confirm your insurance class (Medicare Part B vs. Commercial vs. Medicaid).
2. Ask your prescriber's office whether they will bill your insurance directly under Part B.
3. Request a prior authorization letter template from your provider before the insurer asks.
4. Check current Amgen co-pay card eligibility at the time of each injection cycle.
5. If denied, appeal with a letter that documents your T-score, FRAX score, and any contraindication to oral bisphosphonates (esophageal disease, absorption issues, poor tolerability).

Does Prolia Actually Work? The Clinical Evidence

Yes. Denosumab has one of the most replicated efficacy records of any osteoporosis drug in postmenopausal women. The benchmark trial is FREEDOM.

The FREEDOM Trial

The FREEDOM trial, published in the New England Journal of Medicine in 2009, enrolled 7,868 postmenopausal women aged 60 to 90 with a lumbar spine or total hip T-score between -2.5 and -4.0. Women received either 60 mg denosumab subcutaneously every six months or placebo for three years.

Results at 36 months:

• New vertebral fractures: 2.3% in the denosumab group vs. 7.2% in the placebo group, a 68% relative risk reduction (Cummings et al., NEJM 2009).
• Hip fractures: 0.7% vs. 1.2%, a 40% relative risk reduction.
• Non-vertebral fractures: 6.5% vs. 8.0%, a 20% relative risk reduction.

Those numbers are for postmenopausal women specifically. The trial enrolled no men.

Long-Term FREEDOM Extension

Women who continued denosumab for up to 10 years in the FREEDOM Extension study showed progressive gains in bone mineral density (BMD) at the lumbar spine and hip throughout the extension period, with no plateau observed by year 10. Bone mineral density at the lumbar spine increased a cumulative 21.7% from baseline over 10 years in the long-term extension cohort. Fracture rates in the extension remained low and comparable to the original treatment arm.

What BMD Changes Look Like in Practice

Women commonly ask: "Will I actually see my numbers improve, or just stop getting worse?" Most women prescribed Prolia for postmenopausal osteoporosis see measurable BMD increases at their first follow-up DXA scan, typically scheduled 1 to 2 years after starting treatment. The Menopause Society's 2023 position statement on osteoporosis notes that denosumab produces greater BMD gains than oral bisphosphonates at 12 and 24 months, which can matter clinically for women who start with very low baseline BMD.

Real Patient Reviews: What Women Report

Online reviews for Prolia skew positive for fracture prevention but mixed on tolerability. The following synthesizes Drugs.com ratings, PatientsLikeMe entries, and Reddit threads. These sources reflect a self-selected, motivated population and cannot be treated as representative clinical data.

Positive Patterns

Fracture-free years. The most frequent positive comment across Drugs.com reviews (average rating 3.6 out of 5, based on 300+ reviews as of early 2025) is that women who had sustained fragility fractures before Prolia have gone years without new fractures. Several postmenopausal women in their late 60s and 70s describe DXA scans showing T-score improvements of 0.3 to 0.6 over two to three injection cycles, which correlates with what FREEDOM data would predict.

Convenience. Twice-yearly dosing appeals to women who struggled with weekly or monthly oral bisphosphonate regimens, especially those with esophageal reflux or swallowing difficulty. A Drugs.com reviewer, age 71: "I could never keep down Fosamax without burning. Two shots a year and my bones have improved. That works for me."

Tolerability for GI-sensitive women. Women with a history of Barrett's esophagus or inflammatory bowel disease particularly note denosumab's oral-free route as a reason their clinician chose it over alendronate.

Negative or Mixed Patterns

Muscle and joint pain. A notable minority of reviewers (roughly 20 to 25% of Drugs.com entries) describe new or worsened musculoskeletal pain in the weeks following injection. This is consistent with FDA labeling for Prolia, which lists severe bone, joint, and muscle pain as a post-marketing adverse event.

Injection-site reactions. Redness, mild swelling, and pain at the injection site are among the most commonly reported short-term complaints. These typically resolve within a few days and rarely require intervention.

The discontinuation problem. The most alarming theme in patient forums is what happens when Prolia is stopped. Multiple Reddit users on r/osteoporosis describe being told mid-treatment that their insurer would no longer cover the drug, triggering panic about discontinuation. The concern is clinically founded: stopping denosumab without transitioning to a bisphosphonate causes rapid bone turnover rebound and a risk of multiple spontaneous vertebral fractures within 12 to 24 months. More on this in the discontinuation section below.

Infection risk. Denosumab suppresses RANKL, which plays a role in immune function. Serious infections, including skin infections (cellulitis), urinary tract infections, and endocarditis, appear at higher rates in denosumab-treated patients than placebo in post-marketing reports. Women who are immunocompromised or prone to recurrent UTIs should discuss this with their prescriber before starting.

Who Should Consider Prolia (and Who Should Not)

Women Most Likely to Benefit

Postmenopausal women with established osteoporosis (T-score <-2.5). This is the primary approved indication and where the FREEDOM data applies directly. If you are post-menopause with a fragility fracture history, a very low T-score, or both, denosumab is a guideline-supported option alongside oral and IV bisphosphonates and anabolic agents.

Women who cannot tolerate oral bisphosphonates. Esophageal stricture, Barrett's esophagus, severe GERD, malabsorption syndromes, and inability to remain upright 30 to 60 minutes post-dose are all reasons clinicians choose Prolia over alendronate or risedronate as a first injectable alternative.

Women on aromatase inhibitors for breast cancer. Aromatase inhibitors (AIs) used in hormone receptor-positive breast cancer treatment cause accelerated bone loss. ACOG and ASCO guidelines recognize denosumab as an appropriate bone-protective agent in this setting, and Xgeva (the higher-dose denosumab formulation at 120 mg monthly) is FDA-approved for cancer-related bone protection.

Perimenopausal women with premature ovarian insufficiency (POI). Women with POI who cannot use hormone therapy face an unusually long window of estrogen deficiency and accelerated bone loss. Denosumab may be considered in this group, though evidence in premenopausal women is much thinner than in postmenopausal women.

Women Who Should Not Use Prolia

• Women who are pregnant or trying to conceive (see the dedicated section below).
• Women with hypocalcemia: Prolia lowers calcium further. Correct hypocalcemia before starting and ensure adequate calcium and vitamin D supplementation throughout.
• Women who cannot commit to six-month injection schedules: Missing a dose without a plan creates the rebound fracture risk described above.
• Women with severe kidney impairment (eGFR <30) need careful monitoring; the hypocalcemia risk is higher.

Pregnancy, Lactation, and Contraception: What You Must Know

Denosumab is contraindicated in pregnancy. This is a firm contraindication, not a caution.

Why It Is Contraindicated

Denosumab is a monoclonal antibody that crosses the placenta, particularly in the second and third trimesters. In animal studies, denosumab caused fetal harm including absent lymph nodes, abnormal bone development, and increased post-natal mortality. The FDA's 2023 Prolia prescribing information states that Prolia can cause fetal harm when administered to a pregnant woman and lists it as contraindicated in pregnancy.

Human data are limited to case reports and a small pregnancy exposure registry. Given the mechanism and animal data, clinicians should not prescribe denosumab to women who are pregnant or who plan to become pregnant.

Contraception Requirements

Women of reproductive age who are prescribed denosumab for any indication (for example, premenopausal women on aromatase inhibitors for early breast cancer) must use effective contraception during treatment and for at least five months after the last dose. The five-month window is based on the half-life and expected drug clearance timeline. Discuss your contraception method with your prescriber before your first injection.

Lactation

Whether denosumab transfers into human breast milk is not known. Because IgG antibodies are present in breast milk and because of the potential for serious adverse effects in a nursing infant, the FDA label advises women not to breastfeed during treatment and for at least five months after the final dose. The FDA label does not support breastfeeding concurrent with denosumab therapy.

Reproductive-Years and Fertility Counseling

Prolia is not a standard treatment for premenopausal women with routine osteoporosis risk. If you are under 45 and your clinician is recommending denosumab, ask specifically why a bisphosphonate or hormone therapy was not chosen first, what the plan is if you want to conceive, and how long you would need to wait after stopping before trying to become pregnant.

The Discontinuation Problem: What Happens If You Stop

This deserves its own section because it is the aspect of Prolia that most surprises women, and it is underrepresented in patient-facing materials.

When denosumab is stopped, RANKL-mediated bone resorption rebounds rapidly. A 2017 paper in Osteoporosis International documented cases of multiple vertebral fractures occurring within 7 to 24 months of denosumab discontinuation, particularly in women who stopped without a bridging therapy. The bone loss after stopping can exceed the bone gained during treatment, and it can happen faster than with bisphosphonate discontinuation.

The clinical standard of care is: if you are stopping Prolia for any reason, including cost, insurance loss, or a planned pregnancy, you should receive a bisphosphonate (most commonly zoledronic acid 5 mg IV once) to suppress the rebound. The Menopause Society recommends that clinicians plan this transition at the time Prolia is started, not as an afterthought.

If your insurance is cancelled or you lose coverage mid-treatment, contact your prescriber immediately. Do not simply stop. This is a medical situation that requires a transition plan, not just a billing conversation.

Prolia Across Life Stages: A Quick Reference

| Life Stage | Role of Denosumab | Key Considerations | |---|---|---| | Reproductive years (18-40) | Rarely indicated; case-by-case for POI or cancer-related bone loss | Contraception required; plan for pregnancy before starting | | Perimenopause (40s-early 50s) | Not standard; consider if bone loss is accelerated and HRT is not suitable | Oral bisphosphonates often preferred; data thinner in this group | | Postmenopause (established osteoporosis) | Primary indication, well-supported by FREEDOM data | Plan discontinuation bridging from day one | | Breast cancer, on aromatase inhibitors | Appropriate with oncology co-management | Xgeva (120 mg monthly) for cancer bone metastases; Prolia (60 mg q6m) for AI-associated bone loss | | Age 75+ | Often preferred over bisphosphonates if renal function allows | Monitor calcium closely; infection risk increases with age |

How Prolia Compares to Other Osteoporosis Options

Women often arrive at a Prolia conversation after years on alendronate (Fosamax) or after a first fragility fracture that prompts a more aggressive approach. Here is where Prolia fits relative to other options.

Prolia vs. Oral Bisphosphonates (Alendronate, Risedronate)

Oral bisphosphonates remain the most prescribed first-line treatment for postmenopausal osteoporosis because of their long safety record, low cost (generic alendronate is around $10 to $15 per month), and oral convenience. Prolia produces modestly greater BMD gains at head-to-head time points but has a higher cost and the critical discontinuation risk that bisphosphonates do not carry. The Menopause Society's 2023 statement positions both as appropriate first-line options, with the choice based on tolerability, adherence likelihood, and individual fracture risk profile.

Prolia vs. Zoledronic Acid (Reclast)

Zoledronic acid is a once-yearly IV bisphosphonate that reduced vertebral fracture risk by 70% over three years in the HORIZON trial. It does not carry the rebound risk on discontinuation. For women who want an injectable option without the stop-safely complexity, zoledronic acid is a meaningful alternative. Its cost with insurance is similar to Prolia; without insurance, an infusion runs $1,000 to $1,500 annually.

Prolia vs. Romosozumab (Evenity)

Romosozumab is a newer anabolic/anti-resorptive agent given monthly for 12 months. In the ARCH trial, it reduced vertebral fractures by 73% over 24 months when followed by alendronate, outperforming alendronate alone. It carries a cardiovascular warning. It is typically used for very high-risk women and costs significantly more than Prolia. After 12 months of romosozumab, transition to an anti-resorptive (often denosumab) is standard.

Prolia vs. Teriparatide (Forteo) or Abaloparatide (Tymlos)

These anabolic agents (PTH-related peptides) are daily self-injections with strong fracture reduction data, used for a maximum of two years. They are typically followed by an anti-resorptive like denosumab to preserve the bone gained. Their cash cost exceeds $3,000 per month and access depends heavily on insurance.

Calcium, Vitamin D, and Lifestyle: What Has to Go With Prolia

Denosumab lowers bone resorption but it does not supply the raw materials your bone matrix needs. Calcium and vitamin D deficiency going into Prolia treatment increases the risk of hypocalcemia, which can be serious.

The National Osteoporosis Foundation recommends 1,200 mg of elemental calcium daily (from food and supplements combined) and 800 to 1,000 IU of vitamin D3 daily for postmenopausal women on bone-active therapy. Your clinician may check a 25-hydroxyvitamin D level before your first Prolia injection and supplement to a level above 30 ng/mL.

Resistance and weight-bearing exercise, smoking cessation, and moderation of alcohol all contribute to bone outcomes. A 2019 Cochrane review confirmed that exercise interventions reduce fall risk, which is the proximate cause of most hip fractures, in older women. Prolia does not replace these lifestyle factors. It works alongside them.

A Note on the Evidence Gap for Non-Postmenopausal Women

The FREEDOM trial enrolled postmenopausal women only. Most of what we know about denosumab's fracture reduction comes from that population. Data for premenopausal women with osteoporosis are extrapolated from smaller studies and case series. Data for perimenopausal women specifically are thin. Data for trans women and non-binary people with female reproductive history are essentially absent from published trials.

If you are under 50 and your clinician is recommending Prolia, the evidence base is narrower than it is for an average 68-year-old postmenopausal woman, and that conversation should happen explicitly before you consent to treatment.

WomanRx clinical reviewer Dr. Rachel Goldberg, MD, notes: "The discontinuation risk with Prolia is the single piece of information I wish every woman understood before her first injection. I have seen patients in real distress when insurance coverage lapses mid-treatment and no one told them at the start that stopping without a bridge creates a fracture emergency. That planning conversation needs to happen at visit one, not when the coverage is already gone."